1081MO Efficacy of ipilimumab plus nivolumab or ipilimumab plus fotemustine vs fotemustine in patients with melanoma metastatic to the brain: Primary analysis of the phase III NIBIT-M2 trial
Anna Maria Di Giacomo(University of Siena), Michele Maio(University of Siena), Riccardo Danielli(University of Siena), Mario Mandalà(University of Perugia), Pier Francesco Ferrucci(MultiMedica), Massimo Guidoboni(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Paolo Marchetti(Istituto Dermopatico dell'Immacolata), Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), Ornella Cutaia(University of Siena), Michele Guida(Istituto Tumori Bari), Pietro Quaglino(Department of Medical Sciences), Monica Valente(University of Siena), Diana Giannarelli(Agostino Gemelli University Polyclinic), Elisabetta Gambale(University of Siena), Giovanni Amato(Institute for Experimental Endocrinology and Oncology), Luana Calabrò(University of Siena)
Cited by 7
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
|New England Journal of Medicine|2018|1.9k